Chemometec — December 2021
-
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report 2021: Analysis of Yescarta, Tecartus, Kymriah, Breyanzi, & Abecma
/PRNewswire/ -- The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's...
(www.prnewswire.com)
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
-
Chemometec rykker en klasse op i aktiesegment, da aktien fra 3. januar rykkes fra Midcap-segmentet til Large Cap-segmentet.
Det oplyser selskabet i en meddelelse.Large Cap-segmentet består af virksomheder, hvis markedsværdi overstiger 1 mia. euro. Chemometecs markedsværdi udgør i dag cirka 14 mia. kr.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind